A Unique US-Based Drug Development Company
At KangLaiTe USA our mission is to discover and develop natural therapies to improve the lives of people living with various cancers.
KangLaiTe USA (KLT) is a privately held biotechnology company developing a natural treatment for people living with solid tumor cancers and for cancer-associated anorexia-cachexia syndrome. Our parent company is the Zhejiang Kanglaite Group Co., Ltd., located in Hangzhou, China, and our American headquarters in the Silicon Valley has been in operation for more than 14 years.
Our drug candidates are based on botanical sources, which have been developed as cancer therapies that are in use today in other countries around the world. Our lead product in clinical trials in the United States is Kanglaite Injection (KLTi). Its active pharmaceutical ingredient is derived from coix seeds, a grass seed used in Chinese medicine for over 4,000 years. KLTi has been successfully marketed in China for treatment of patients with advanced non-small cell lung cancer (NSCLC) and hepatocellular cancer.
More than 20 years ago, Dr. Dapeng Li, a renowned Chinese pharmacologist, saw the true promise of coix lacryma-jobi seeds in the treatment of cancer and made it his mission to bring this powerful botanical to the world. Since then, KLT has been committed to creating a vision of hope in cancer treatment.